Abiomed (NSDQ:ABMD) announced that it received FDA emergency use authorization (EUA) for its Impella RP for use with COVID-19-related right heart failure. The Impella RP temporary heart pump provides circulatory support for patients with right side ventricular failure. It won FDA approval in September 2017 for such an indication and in October 2019 Abiomed reported real-world data […]
Abiomed stock up amid Street-beating Q4 profits, news of Breethe acquisition
Abiomed (NSDQ:ABMD) shares are up 10% in morning trading today after the company posted Street-beating Q1 results and announced the acquisition of Breethe and its potential coronavirus-fighting tech. The Danvers, Mass.-based maker of circulatory support devices — including Impella heart pumps — posted profits of $31.8 million, or 70¢ per share, on sales of $206.7 million […]
Judge tosses wrongful termination suit against Abiomed
Abiomed (NSDQ:ABMD) has convinced a federal judge that whistleblower Max Bennett had no basis on which to claim the company fired him in retaliation for his investigation of federal False Claims Act violations. Judge Indira Talwani ruled on Tuesday that “no reasonable jury could find that Bennett had engaged in protected activity or that he was […]
Abiomed beats on earnings, misses on revenue in Q3 results
Abiomed (NSDQ:ABMD) posted third-quarter results that beat the earnings consensus on Wall Street, but missed on revenue. The Danvers, Mass.-based company reported profits of $69.2 million, or $1.51 per share, on sales of $221.6 million for the three months ended Dec. 31, 2019, for a bottom-line gain of 54.3% sales growth of 10.5% compared with Q3 […]
Journal editors say study of Abiomed’s Impella pumps limited
This article has been updated with a comment from Abiomed. A medical journal editorial has cast doubt on the findings of a research study that sent shares in Abiomed (NSDQ:ABMD) down sharply in November. The editorial in the journal Circulation said the study’s methodology had several limitations and called for randomized controlled trials (RCTs) to determine […]
Abiomed slips 13% on lower forecast
Shares in Abiomed (NSDQ:ABMD) fell nearly 13% this morning after the company issued revenue guidance that missed Wall Street expectations. The Danvers, Mass.-based company said in an SEC filing that it expects sales of $221.6 million for the third quarter of its fiscal 2020 year, which ended Dec. 31, 2019. While that figure is 10% […]
New trial for Abiomed’s Impella looks for heart failure reduction
Heart pump company Abiomed (NSDQ:ABMD) has begun a clinical trial to determine whether pumping blood from the left ventricle after a heart attack will reduce the amount of dead tissue. The ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) randomized controlled trial will explore whether using the company’s Impella heart pump to unload the left ventricle for […]
FDA: Abiomed Impella RP survival rate steady when appropriate patients are implanted
The survival rate of right-heart failure patients treated with the Abiomed (NSDQ:ABMD) Impella RP heart pump remained about the same during the latest round of post-approval studies, according to the FDA. That latest rate of survival 30 days post-explant, post-discharge survival or switch to another therapy rate was 72.7%, or 16 out of 22 patients among […]
Appeals court tosses former Abiomed Asia exec’s lawsuit
This article has been updated with a comment from Abiomed. A federal appeals court has dismissed the wrongful termination law suit of a former Asia VP for Abiomed (NSDQ:ABMD). The three-judge panel ruled on Nov. 27 that Keisuke Suzuki failed to prove that Abiomed owed him compensation in the form of company stock options for […]
Abiomed stock recovers some as company further questions critical Impella studies
Shares of heart pump company Abiomed (NSDQ:ABMD) recovered a bit today — a day after the company’s stock took a 20% dive after two critical studies came out of American Heart Association’s Scientific Sessions. The two separate studies — one led by researchers in St. Louis, the other out of San Francisco — suggested potentially serious complications […]
BREAKING: Abiomed stock down 20% after new research raises questions about Impella
Shares of heart pump company Abiomed (NSDQ:ABMD) fell today after research released over the weekend suggested potentially serious complications involving the company’s Impella heart pumps. Abiomed stock was down more than 20%, to $178.09 per share, by the close of trading after news of the two studies came out of the American Heart Association’s Scientific Sessions […]
- 1
- 2
- 3
- …
- 26
- Next Page »
